This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

SLW: The part of dairy that is very well-positioned to assist consumers on their GLP-1 journey is yogurt. The functional ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

compiled by the Official Charts Company. The UK Top 40 is broadcast on BBC Radio 1, the Top 100 is published exclusively on OfficialCharts.com. View the biggest songs of 2024 so far.

We summarize the approximate costs in the table below ... while single-dose vials come in limited dose ranges but cost less. To learn more about GLP-1 drugs, read our articles on Mounjaro ...

Josh Gad is opening up about the weight loss success he’s had with GLP-1 medication — and sharing some of the conflicted feelings he’s had along the way. “I’m on a GLP-1 … this is the ...

DeepSeek hit No. 1 on the Apple app store's Top Free Apps chart days after the Chinese startup released its flagship model, R1. DeepSeek, led by the Chinese quant hedge fund manager Liang Wenfeng ...

In a meta-analysis of nine randomized controlled trials, adults had an average lean mass loss of 2.5 kg with GLP-1 therapy ... found once-weekly exenatide 2 mg was associated with a greater ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...

“Our study confirms the increased likelihood of being diagnosed with what appears to be low-risk thyroid cancer after treatment with GLP-1 RAs — but not because patients treated with GLP-1 RAs ...